The Abiding Myth of Innovation
The underlying theme of this year's Phoenix meeting was the need to carefully manage through times of rapid change and discontinuity and select appropriate corporate cultures. The medical device industry is, in large measure, built on the notion that small companies deliver the lion's share of innovative technology. But the critical role large companies play in bringing those products to market undermines, to a degree, the power small companies have as innovators. Thus, side by side with the value that innovative or disruptive technology brings is the power of incumbency and entrenched interests. And as the e-health revolution hits the skids, no segment better illustrates the ability of incumbency to take control over the discontinuity that disruptive technology brings than the Internet. There are, in fact, several reasons why even the most innovative devices fall short of being truly disruptive, including the long clinical and regulatory paths they must travel, the aversion most physicians have to products that make them change the way they practice medicine, and the critical role of big companies in marketing.
You may also be interested in...
Gilead is closely evaluating the situation for remdesivir in India as the country tackles shortages of the drug, which has several local licensees, with instances of black marketing adding to the local woes. The US firm clearly will not want any momentum towards possible compulsory licensing as initiated by Hungary and Russia, even as Indian firms have cut prices of the antiviral.
Amid a case of re-infection of a vaccinated healthcare worker in western China’s Xi’an city, and ongoing debate over domestic vaccines' efficacy, increasing attention is being paid in China to raising inoculation rates for COVID-19 and moving towards herd immunity.
The company announced new research investments and partnerships with the American Diabetes Association and the T1D Exchange to address racial disparities in treatment of diabetes.